Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: mplaut who wrote (12181)	7/5/2013 11:51:53 AM
From: NTTG	2 Recommendations Recommended By boomertree2 Pogeu Mahone Respond to of 13111

Had PVCT taken a more serious approach to their clinical and basic science R&D program I might be able to say more positive things about them. They didn't, so I can only comment on the little bits they have done... But sometimes, dumb luck happens....... I would be interested in knowing more about the splenocyte transfer studies the company eluded to during an investor meeting several years ago, and the recently reported IL response by isolated splenocytes exposed to tumor cells. My positive comments on both of these points are a matter of public record here. However I cautioned at the time, and now, that the numbers are very small in both reports and the statistical significance they reported is very fragile. Using a frame of perspective you are familiar with, had the MGT team each taken a 200 K cut in their near 7 figure pay and benefits over the years, more convincing evidence would have been forthcoming, and the story would have been clearer and more 'sellable' to potential partners. For some reason, MGT felt they wanted their money up front, I wonder why?